Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 2
1967 9
1968 13
1970 2
1971 1
1978 5
1979 2
1980 4
1981 5
1982 1
1983 5
1984 3
1985 5
1986 7
1987 7
1988 3
1990 1
1991 2
1992 1
1993 1
1994 1
1995 3
1996 5
1997 5
1998 7
1999 2
2000 7
2001 4
2002 5
2003 7
2004 4
2005 6
2006 2
2007 15
2008 13
2009 9
2010 14
2011 14
2012 13
2013 10
2014 13
2015 17
2016 14
2017 8
2018 14
2019 8
2020 23
2021 15
2022 16
2023 17
2024 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
The Emerging Role of the Microbiota in Breast Cancer Progression.
Bernardo G, Le Noci V, Di Modica M, Montanari E, Triulzi T, Pupa SM, Tagliabue E, Sommariva M, Sfondrini L. Bernardo G, et al. Cells. 2023 Jul 27;12(15):1945. doi: 10.3390/cells12151945. Cells. 2023. PMID: 37566024 Free PMC article. Review.
Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study.
Schmitz S, Caballero C, Locati LD. Schmitz S, et al. Eur J Cancer. 2018 Nov;104:219-223. doi: 10.1016/j.ejca.2018.07.315. Epub 2018 Oct 6. Eur J Cancer. 2018. PMID: 30301582
A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. ...This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and pro …
A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squa …
A nociceptive amygdala-striatal pathway for chronic pain aversion.
Wojick JA, Paranjapye A, Chiu JK, Mahmood M, Oswell C, Kimmey BA, Wooldridge LM, McCall NM, Han A, Ejoh LL, Chehimi SN, Crist RC, Reiner BC, Korb E, Corder G. Wojick JA, et al. bioRxiv [Preprint]. 2024 Feb 13:2024.02.12.579947. doi: 10.1101/2024.02.12.579947. bioRxiv. 2024. PMID: 38405972 Free PMC article. Preprint.
Here, we show that the same BLA(noci) ensemble neurons are required for both acute and chronic neuropathic pain behavior. ...We thus examined the brain-wide targets of the BLA(noci) ensemble and uncovered a previously undescribed nociceptive hotspot of the nucleus a …
Here, we show that the same BLA(noci) ensemble neurons are required for both acute and chronic neuropathic pain behavior. ...We thus …
Efficient Implementation of NOCI-MP2 Using the Resolution of the Identity Approximation with Application to Charged Dimers and Long C-C Bonds in Ethane Derivatives.
Yost SR, Head-Gordon M. Yost SR, et al. J Chem Theory Comput. 2018 Sep 11;14(9):4791-4805. doi: 10.1021/acs.jctc.8b00697. Epub 2018 Aug 28. J Chem Theory Comput. 2018. PMID: 30063831
An efficient implementation of the perturb-then-diagonalize nonorthogonal configuration interaction method with second-order Moller-Plesset perturbation theory (NOCI-MP2) is presented. Relative to other low scaling multireference perturbation theories, NOCI-MP2 ofte …
An efficient implementation of the perturb-then-diagonalize nonorthogonal configuration interaction method with second-order Moller-Plesset …
Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Moschonis G, Siopis G, Jung J, Eweka E, Willems R, Kwasnicka D, Asare BY, Kodithuwakku V, Verhaeghe N, Vedanthan R, Annemans L, Oldenburg B, Manios Y; DigiCare4You Consortium. Moschonis G, et al. Lancet Digit Health. 2023 Mar;5(3):e125-e143. doi: 10.1016/S2589-7500(22)00233-3. Lancet Digit Health. 2023. PMID: 36828606 Free article.
Standard and reference-based conditional mean imputation.
Wolbers M, Noci A, Delmar P, Gower-Page C, Yiu S, Bartlett JW. Wolbers M, et al. Pharm Stat. 2022 Nov;21(6):1246-1257. doi: 10.1002/pst.2234. Epub 2022 May 19. Pharm Stat. 2022. PMID: 35587109 Free PMC article.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D. Schöffski P, et al. Eur J Cancer. 2010 Aug;46(12):2206-15. doi: 10.1016/j.ejca.2010.03.039. Epub 2010 May 13. Eur J Cancer. 2010. PMID: 20471824 Clinical Trial.
351 results